Home › Cervical Cancer › NCT05372484

Rice Technologies for Cervical Cancer Screening and Diagnosis

Assessment of New Technologies for the Screening and Diagnosis of Cervical Cancer in Mozambique, A Study to be Conducted in Maputo Central Hospital, Mavalane and Jose Macamo General Hospitals and Mavalane Health Center

Who can join

Ages 25 to 49 · Women

Inclusion Criteria:

1. 25 - 49 year old women
2. Women with a positive cervical cancer screening test (abnormal cytology, positive VIA and/or positive HPV test)
3. Women with intact cervix
4. Women who are not pregnant and with a negative pregnancy test (within 14 days from the date of enrollment) ) and not currently breastfeeding
5. Willing and capable of providing informed consent

Exclusion Criteria:

1. Women under 25 or over 49 years old
2. Women who have undergone a total hysterectomy (with removal of the cervix)
3. Women who are pregnant or breastfeeding

About the study

The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.

What is being tested

• Multimodal optical imaging (device)

Sponsor: M.D. Anderson Cancer Center · Participants: 678 · Started: Mar 24, 2021

Contact the study team

• Mila Salcedo, MD, PhD · Phone: (832) 696-6794

Official record on ClinicalTrials.gov — NCT05372484

Locations in the U.S.

Conditions

• Cervical Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.